Name | Validate

Amount in Euro(s)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transactions ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
															In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments						
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loans/ advances/ intercorporate deposits/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilized by the ultimate recipient of funds (endusage)	Notes.
Add	Delete																								
1	GlaxoSmithKline Pharmaceuticals Limited		Biddle Sawyer Limited		Subsidiary	Any other transaction	Rendering of services	500.62	Ok			500.62	0.00	0.00											
2	GlaxoSmithKline Pharmaceuticals Limited		Glx ao S.mKiiNor Biologicals S.A., Belgium		Fellow subsidiary	Any other transaction	Rendering of services	7608.54	Ok			7608.54	0.00	0.00											
3	GlaxoSmithKline Pharmaceuticals Limited		GlaxoSmithKline Egypt SAE		Fellow subsidiary	Any other transaction	Rendering of services	162.62	Ok			162.62	0.00	0.00											
4	GlaxoSmithKline Pharmaceuticals Limited		G SmoSmiKline Pharma India Pvt. Ltd.		Fellow subsidiary	Any other transaction	Rendering of services	75.78	Ok			75.78	0.00	0.00											
5	GlaxoSmithKline Pharmaceuticals Limited		GlaxoSmithKline Services Unlimited		Fellow subsidiary	Any other transaction	Rendering of services	247.13	Ok			247.13	0.00	0.00											
6	GlaxoSmithKline Pharmaceuticals Limited		GSK E India Global Services Private Limited		Fellow subsidiary	Any other transaction	Rendering of services	295.61	Ok			295.61	0.00	0.00											
7	GlaxoSmithKline Pharmaceuticals Limited		GlaxoSmithKline Philippines Inc		Fellow subsidiary	Any other transaction	Rendering of services	96.07	Ok			96.07	0.00	0.00											
8	GlaxoSmithKline Pharmaceuticals Limited		Glaxo Operations UK Limited, U.K		Fellow subsidiary	Any other transaction	Rendering of services	257.17	Ok			257.17	0.00	0.00											
9	GlaxoSmithKline Pharmaceuticals Limited		GlaxoSmithKline Services Unlimited, U.K.		Fellow subsidiary	Any other transaction	Receiving of Services	239.58	Ok			239.58	0.00	0.00											
10	GlaxoSmithKline Pharmaceuticals Limited		Biddle Sawyer Limited		Subsidiary	Any other transaction	Receiving of Services	5.70	Ok			5.70	0.00	0.00											
11	GlaxoSmithKline Pharmaceuticals Limited		G ka a ciler GMDlee Pte Limited, Singapore		Fellow subsidiary	Any other transaction	Receiving of Services	31.23	Ok			31.23	0.00	0.00											
12	GlaxoSmithKline Pharmaceuticals Limited		Biddle Sawyer Limited		Subsidiary	Any other transaction	Outstanding balance	0.00	nil			0.00	435.33	435.33											
13	GlaxoSmithKline Pharmaceuticals Limited		Glaxo Operations UK Limited, U.K		Fellow subsidiary	Any other transaction	Outstanding balance	0.00	nil			0.00	-56.19	0.00											
14	GlaxoSmithKline Pharmaceuticals Limited		Glx ao S.mKiiNor Biologicals S.A., Belgium		Fellow subsidiary	Any other transaction	Outstanding balance	0.00	nil			0.00	-2696.96	-9716.86											
15	GlaxoSmithKline Pharmaceuticals Limited		GlaxoSmithKline Egypt SAE		Fellow subsidiary	Any other transaction	Outstanding balance	0.00	nil			0.00	16.47	108.68											
16	GlaxoSmithKline Pharmaceuticals Limited		GlaxoSmithKline Export Limited, U.K.		Fellow subsidiary	Any other transaction	Outstanding balance	0.00	nil			0.00	-2707.19	-2658.91											
17	GlaxoSmithKline Pharmaceuticals Limited		GlaxoSmithKline LLC, U.S.A		Fellow subsidiary	Any other transaction	Outstanding balance	0.00	nil			0.00	-76.70	0.00											
18	GlaxoSmithKline Pharmaceuticals Limited		G SmoSmiKline Pharma India Pvt. Ltd.		Fellow subsidiary	Any other transaction	Outstanding balance	0.00	nil			0.00	5.82	-106.39											
19	GlaxoSmithKline Pharmaceuticals Limited		Glxa cnSm KIK Sr a Ro or ach R. Zug, Switzerland		Fellow subsidiary	Any other transaction	Outstanding balance	0.00	nil			0.00	-737.31	-737.31											
20	GlaxoSmithKline Pharmaceuticals Limited		GlaxoSmithKline Services Unlimited, U.K.		Fellow subsidiary	Any other transaction	Outstanding balance	0.00	nil			0.00	-1809.38	-866.60											
21	GlaxoSmithKline Pharmaceuticals Limited		G ka a S. m a Ki Sn a Trading Services S.r.l. Bi S.A. d. C.V. (GSK SP		Fellow subsidiary	Any other transaction	Outstanding balance	0.00	nil			0.00	10.23	0.00											
22	GlaxoSmithKline Pharmaceuticals Limited		GSK E India Global Services Private Limited		Fellow subsidiary	Any other transaction	Outstanding balance	0.00	nil			0.00	47.09	-23.71											
23	GlaxoSmithKline Pharmaceuticals Limited		GlaxoSmithKline Philippines Inc		Fellow subsidiary	Any other transaction	Outstanding balance	0.00	nil			0.00	132.69	74.97											
24	GlaxoSmithKline Pharmaceuticals Limited		Mr. Uday Chawla		Key management personnel	Any other transaction	Employee benefits	658.06	nil			658.06	0.00	0.00											
25	GlaxoSmithKline Pharmaceuticals Limited		AJAY NAGWARE		Key management personnel	Any other transaction	Employee benefits	336.30	nil			336.30	0.00	0.00											
26	GlaxoSmithKline Pharmaceuticals Limited		Bhushan Dhobkar		Key management personnel	Any other transaction	Employee benefits	658.52	nil			658.52	0.00	0.00											
27	GlaxoSmithKline Pharmaceuticals Limited		Biddle Sawyer Limited		Subsidiary	Interest received		15.00	nil			15.00	400.00	450.00					Loan	7.72%	9 years	Unsecured	Working capital loan	
28	GlaxoSmithKline Pharmaceuticals Limited		Biddle Sawyer Limited		Subsidiary	Loan		2000.00	nil			2000.00	0.00	0.00											
29	GlaxoSmithKline Pharmaceuticals Limited		Glx ao S.mKiiNor Biologicals S.A., Belgium		Fellow subsidiary	Purchase of goods or services		17528.87	nil			17528.87	0.00	0.00											
30	GlaxoSmithKline Pharmaceuticals Limited		GlaxoSmithKline Export Limited, U.K.		Fellow subsidiary	Purchase of goods or services		2932.74	nil			2932.74	0.00	0.00											
31	GlaxoSmithKline Pharmaceuticals Limited		G SmoSmiKline Pharma India Pvt. Ltd.		Fellow subsidiary	Purchase of goods or services		1537.80	nil			1537.80	0.00	0.00											
32	GlaxoSmithKline Pharmaceuticals Limited		Biddle Sawyer Limited		Subsidiary	Purchase of goods or services		807.10	nil			807.10	0.00	0.00											
33	GlaxoSmithKline Pharmaceuticals Limited		PT Glaxo wellcome Indonesia		Fellow subsidiary	Sale of goods or services		17.61	nil			17.61	0.00	0.00											
Total value of transaction during the reporting period												35242.05													

Notes:

1. The details in this format are required to be provided for all transactions undertaken during the reporting period. However, opening and closing balances, including commitments, to be disclosed for existing related party transactions even if there is no new related party transaction during the reporting period.
2. Where a transaction is undertaken between members of the consolidated entity (between the listed entity and its subsidiaries or between subsidiaries), it may be reported once.
3. Listed banks shall not be required to provide the disclosures with respect to related party transactions involving loans, inter-corporate deposits, advances or investments made or given by the listed banks.
4. In case any financial indebtedness for year ending March 31, this information has to be provided for six months ended September 30 and six months ended March 31.
5. Transactions with foreign subsidiaries ending in other months, the six months period shall apply accordingly.
6. Each type of related party transaction (for e.g. sale of goods/services, purchase of goods/services or whether it involves a loan, inter-corporate deposit, advance or investment) with a single party shall be disclosed separately and there should be no clubbing or netting of transactions of same type.

However, transactions with the same counterparty of the same type may be aggregated for the reporting period. For instance, sale transactions with the same party may be aggregated for the reporting period and purchase transactions may also be disclosed in a similar manner. There should be no netting off for sale and purchase transactions. Similarly, loans advanced to and received from the same counterparty should be disclosed separately, without any netting off.

7. In case of a multi-year related party transaction:
a. The value of the related party transaction as approved by the audit committee shall be disclosed in the column "Value of the related party transactions approved by the audit committee".
b. The value of the related party transaction ratified by the audit committee shall be disclosed in the column "Value of the related party transaction ratified by the audit committee".
c. The value of the related party transaction undertaken in the reporting period shall be reported in the column "Value of related party transaction during the reporting period".

8. "Cost" refers to the cost of borrowed funds for the listed entity. 9. Transactions such as acceptance of fixed deposits by banks/NBFCs, undertaken with related parties, at the terms uniformly applicable (offered to all shareholders/ public shall also be reported.